Literature DB >> 20544660

Surgical debridement with muscle flap transposition and systemic teicoplanin therapy for infected hip arthroplasty.

Gabriella d'Ettorre1, Francesco Marchetti, Giancarlo Ceccarelli, Francesca Gizzi, Francesca Tierno, Marco Falcone, Mario Venditti, Bruno Carlesimo, Vincenzo Vullo.   

Abstract

The use of muscle flaps is now accepted as a method for coverage of infected wounds. To obtain complete eradication of infection following hip arthroplasty surgery is combined with antibiotic treatment. Aggressive debridment to remove devitalized tissue followed by vastus lateralis muscle flap transposition may improve the likelihood of success in certain challenging cases. We report two cases of prosthetic joint infection treated by aggressive debridment and vastus lateralis transposition with associated appropriate antibiotic therapy. Complete recovery of functional status was observed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544660     DOI: 10.1177/112070001002000218

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  3 in total

1.  Surgical technique: vastus medialis and vastus lateralis as flap transfer for knee extensor mechanism deficiency.

Authors:  Leo A Whiteside
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

Review 2.  A Devasting Course of an Iliopsoas Muscle Abscess Subsequently Leading to Septic Shock, Septic Hip Arthritis, and Extended Gluteal Soft Tissue Necroses in an Elderly Immunocompromised Patient with Multiple Carcinomas: A Case Report and Brief Review of Literature.

Authors:  Ingo Schmidt
Journal:  Open Orthop J       Date:  2018-05-31

Review 3.  Use of muscular flaps for the treatment of hip prosthetic joint infection: a systematic review.

Authors:  Giuseppe Rovere; Domenico De Mauro; Marco D'Orio; Camillo Fulchignoni; Maria Rosaria Matrangolo; Carlo Perisano; Antonio Ziranu; Elisabetta Pataia
Journal:  BMC Musculoskelet Disord       Date:  2021-12-23       Impact factor: 2.562

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.